Advancing Plasmodium vivax vaccines: A novel multistage antigen meets mRNA technology
According to the WHO World Malaria Report 2025, Plasmodium vivax malaria accounts for approximately 10 million symptomatic cases annually.1 Although less lethal than Plasmodium falciparum, acute P. vivax infection may cause a cytokine storm, severe disease and death,2 particularly among vulnerable populations and remains a major public health problem in Asia, Latin America, and parts of Africa. Furthermore, the high prevalence of silent asymptomatic cases that remain untreated, undermines the measures to control disease transmission,3 which are primarily based on treatment of symptomatic cases and use of insecticide for vector elimination.
Authors
- Denis Alexis Molina Molina (ORCID: https://orcid.org/0000-0001-8609-7015)
- Ricardo T. Gazzinelli (ORCID: https://orcid.org/0000-0003-2427-7699)
Institutions
- Universidade Federal de Minas Gerais (BR)
- Fiocruz Minas (BR)
- Fundação Oswaldo Cruz (BR)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.omtn.2026.103176
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00